About the Authors

Winfried M. Amoaku

Winfried.Amoaku@nottingham.ac.uk

Affiliation University of Nottingham, Academic Ophthalmology, Division of Clinical Neurosciences, and Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

Richard P. Gale

Affiliation York Teaching Hospital NHS Foundation Trust, York, United Kingdom

Andrew J. Lotery

Affiliation Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

Geeta Menon

Affiliation Frimley Park Hospital NHS Foundation Trust, Frimley, United Kingdom

Sobha Sivaprasad

Affiliation NIHR Moorfields Biomedical Research Centre, King’s College Hospital NHS Foundation Trust, London, United Kingdom

Jennifer Petrillo

Current address: Biogen Idec, Global Market Access, Cambridge, MA, United States of America

Affiliation Novartis Pharma AG, Basel, Switzerland

Jennifer Quinn

Current address: Otsuka Pharmaceutical Europe Ltd, Wexham, United Kingdom

Affiliation Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom

Competing Interests

W. Amoaku has been Principal Investigator on clinical trials sponsored by Allergan, Bausch and Lomb, and Novartis, has been a consultant for Novartis, Allergan, Bayer, Alimera, Alcon and Thrombogenics and has received travel grants from Novartis and Bayer. His institution has received grants from Novartis and Allergan. R. Gale is Principal Investigator on clinical trials sponsored by Novartis, has received honoraria from Novartis, and has attended advisory board meetings for Novartis, Bayer, Allergan and Alimera. A. Lotery is Principal Investigator on clinical trials sponsored by Novartis, has received honoraria from Novartis and has attended advisory board meetings for Novartis, Bayer and Alimera. His institution has received educational grants from Novartis. G. Menon has been a Principal Investigator on clinical trials sponsored by Novartis, has received honoraria from Novartis and has attended advisory board meetings for Novartis, Allergan, Bayer, Alcon, Alimera and Thrombogenics. Her institution has received educational grants from Novartis. S. Sivaprasad has received research grants and travel grants and attended advisory board meetings for Alcon, Alimera, Allergan, Bayer, Novartis and Roche. Her institution has received educational grants from Novartis, Bayer and Allergan. J. Petrillo was an employee of Novartis Pharma AG, Basel, Switzerland. J. Quinn was an employee of Novartis Pharmaceuticals UK Ltd, Frimley, UK while the study was conducted. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: WA AL GM. Performed the experiments: WA RG SS. Analyzed the data: WA RG SS JP JQ. Contributed reagents/materials/analysis tools: WA RG SS JP. Wrote the paper: WA RG AL GM SS JP JQ.